New hope for Tough-to-Treat colon cancer
Disease control
Not yet recruiting
This study is testing whether adding a new immunotherapy drug (aipalolitovorelizumab) to standard chemotherapy and another targeted drug (bevacizumab) works better for people with advanced colorectal cancer that has spread and has a specific genetic change called BRAF V600E. The …
Phase: PHASE2 • Sponsor: Yanqiao Zhang • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC